-
Harbour BioMed and Moderna Ink Licensing Deal for Oncology Immunotherapies
•
Harbour BioMed (HKG: 2142), a biotech company with operations in the United States, the Netherlands, and Suzhou, China, has announced a licensing agreement between its wholly owned subsidiary Nona Biosciences and US mRNA specialist ModernaTX, Inc. (NASDAQ: MRNA). The collaboration will focus on discovering and developing nucleic acid-based immunotherapies for…
-
CStone’s PD-L1 Inhibitor Sugemalimab Achieves Primary Endpoint in Gastric Cancer Study
•
China-based CStone Pharmaceuticals (HKG: 2616) has announced that its GEMSTONE-303 study for the programmed death-ligand 1 (PD-L1) inhibitor sugemalimab, combined with chemotherapy as a first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) with PD-L1 expression ≥ 5%, has reached the primary endpoint of progression-free survival (PFS). This…
-
BeiGene’s Brukinsa Receives Marketing Approval in Brazil
•
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that it has received marketing approval in Brazil for its Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib). The in-house developed drug is now approved for the treatment of Waldenström’s macroglobulinemia (WM) and relapsed/refractory (r/r) marginal zone lymphoma (MZL)…
-
Sinocelltech’s SCTV01E Vaccine Receives NMPA Approval for Phase II Study
•
China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a bridging Phase II clinical study assessing the safety and immunogenicity of its SCTV01E vaccine. The quadrivalent (Alpha + Beta + Delta + Omicron variants) S trimer protein…
-
3SBio’s Thrombopoietin Study in Pediatric ITP Reaches Primary Endpoint
•
China-based 3SBio Inc. (HKG: 1530) has announced that its multi-center, randomized, double-blind, placebo-controlled study assessing the safety, efficacy, and pharmacokinetics of thrombopoietin in chronic primary immune thrombocytopenia (ITP) in children or adolescents has reached its pre-set primary endpoint. The results of the statistical analysis showed that the study group’s superiority…
-
Zenas BioPharma Completes $118M Series B Financing to Advance Obexelimab
•
Autoimmune disease drug developer Zenas BioPharma, which is based in the US and China, has announced the completion of a Series B financing round at USD 118 million. The round was led by Enavate Sciences, with participation from Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal…
-
LianBio Initiates Phase I Study of SHP2 Inhibitor BBP-398 in China
•
Sino-US biotech LianBio has announced the first patient dosing in a Phase I clinical study for its SHP2 inhibitor BBP-398 in Chinese patients with advanced solid tumors. This marks a significant step forward in the development of BBP-398, which targets the SHP2 protein-tyrosine phosphatase. SHP2 links growth factor, cytokine, and…
-
Innovex Medical Files for IPO in Hong Kong to Boost Product Development
•
Innovex Medical Co., Ltd, a non-vascular interventional surgery solutions provider based in Shanghai, has filed an initial public offering (IPO) with the Hong Kong Stock Exchange. The IPO is co-sponsored by Goldman Sachs and CICC. While the price has not been disclosed at this stage, the proceeds will be used…
-
Ascentage Pharma Gains CDE Approval for Phase I Study of APG-5918
•
Suzhou-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the Center for Drug Evaluation (CDE) to conduct a multi-center, open-label, dose escalation and expansion Phase I study. The study will assess the safety, pharmacokinetics, and efficacy of its embryonic ectoderm development (EED) inhibitor APG-5918. The drug…
-
Zai Lab Reports 33% YOY Revenue Growth in Q3 2022
•
Chinese biopharmaceutical firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q3 2022 earnings report, showing total revenues of USD 57.5 million for the three-month period, up 33% year-on-year (YOY) and a 19% increase compared to USD 43.1 million for the same period in 2021. Research and Development (R&D)…
-
GSK Partners with CASPC to Advance HIV Sustained Care Advocacy in China
•
The 5th China International Import Expo (CIIE) saw the unveiling of a partnership between GlaxoSmithKline (GSK, NYSE: GSK) and the Chinese Association of STD and AIDS Prevention and Control (CASPC). The collaboration is part of an HIV Sustained Care Advocacy project initiated by the UK major and its joint venture…
-
3SBio Receives NMPA Review for Pediatric ITP Thrombopoietin Filing
•
China-based 3SBio Inc. (HKG: 1530) has announced that the National Medical Products Administration (NMPA) has accepted another market filing for its recombinant thrombopoietin for the treatment of persistent or chronic primary immune thrombocytopenia (ITP) in children or adolescents. This marks a significant step forward in expanding the therapeutic indications for…
-
Boston Scientific Partners with Omron for Atrial Fibrillation Management
•
US-based Boston Scientific Corporation (NYSE: BSX) has announced a partnership with Japan-based Omron Healthcare at the 5th China International Import Expo (CIIE). The collaboration is focused on enhancing the management of cardiovascular and cerebrovascular diseases, particularly atrial fibrillation. The two companies will integrate their product and resource advantages to bolster…
-
Takeda Partners with AWS and Accenture to Launch Innovation Incubator at CIIE
•
The 5th China International Import Expo (CIIE) saw the announcement of a partnership between Takeda Pharmaceutical Co., Ltd (TYO: 4502) and US firms Amazon Web Services (AWS) and Accenture. The collaboration also marks the initiation of “TakedaSpark+”, an innovation incubation platform launched by the Japan-based firm in 2021. Through this…
-
Betta Pharmaceuticals’ BPI-D0316 Shows Promise in Phase II/III Lung Cancer Study
•
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced the summary report of a Phase II/III study for its third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) BPI-D0316. The study evaluated the drug as a first-line treatment for naïve locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR…
-
BeiGene Reports 88% YOY Revenue Growth in Q3 2022
•
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) released its Q3 2022 earnings report, showing robust growth with revenues reaching USD 387.6 million, an 88% year-on-year (YOY) expansion. Sales from products totaled USD 349.5 million during the period, up 82% YOY, driven primarily by Brukinsa (zanubrutinib) and the…
-
Shandong Xinhua and Bayer Announce Strategic Partnership at CIIE
•
A strategic partnership between China-based Shandong Xinhua Pharmaceutical Co., Ltd (HKG: 0719) and Bayer Consumer Care AG was unveiled at the 5th China International Import Expo (CIIE) meeting. The collaboration aims to leverage the respective strengths of both companies to construct new mechanisms of cooperation in the medical and healthcare…
-
Medtronic Partners with Shanghai JiaHui Hospital at CIIE
•
US-based Medtronic Inc. (NYSE: MDT) has announced a partnership with Shanghai JiaHui International Hospital, unveiled at the 5th China International Import Expo (CIIE) held this week. The collaboration aims to enhance patient services, upgrade supply chains, and implement clinical solutions, among other initiatives. Financial details of the partnership were not…
